Holen Sie sich die Stockscreener-App
0.9172
11.14%
0.0919
Handel nachbörslich:
.95
0.0328
+3.58%
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
Humacyte (HUMA) director Kathleen Sebelius purchases 56,818 shares at $0.88 - Stock Titan
Humacyte (HUMA) director adds 11,000 shares at about $0.89 - Stock Titan
Humacyte (HUMA) CFO executes 45,887-share sell-to-cover trade for RSU taxes - Stock Titan
Humacyte (HUMA) CMO executes 45,887-share tax sell-to-cover under 10b5-1 plan - Stock Titan
Humacyte’s Symvess added to VA hospital contract system - Investing.com
Humacyte’s Symvess added to VA hospital contract system By Investing.com - Investing.com Australia
VA hospitals to get easier access to Humacyte Symvess product - Stock Titan
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization - Insider Monkey
[144] Humacyte, Inc. SEC Filing - Stock Titan
Humacyte, Inc. (HUMA) reports Q1 loss, misses revenue estimates - MSN
Number of shareholders of Humacyte, Inc. – NASDAQ:HUMA - TradingView
HUMA Should I Buy - Intellectia AI
Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY) - The Globe and Mail
Humacyte, Inc. (HUMA) stock declines while market improves: Some information for investors - MSN
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Does Humacyte’s (HUMA) Nasdaq Notice Quietly Reframe Its Financing Flexibility And Clinical Adoption Story? - simplywall.st
H.C. Wainwright reiterates Humacyte stock rating at buy, $3 target - Investing.com UK
Humacyte, Inc. (NASDAQ:HUMA) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright reiterates Humacyte stock rating at buy, $3 target By Investing.com - Investing.com South Africa
Barclays Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
HUMACYTE ($HUMA) Releases Q1 2026 Earnings - Moomoo
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $1.5 - Moomoo
HUMA Financials: Income Statement, Balance Sheet & Cash Flow | Humacyte Inc - Stock Titan
Humacyte (NASDAQ: HUMA) posts Q1 2026 loss and flags going concern risk - Stock Titan
MSN Money - MSN
Humacyte, Inc. Stock 12‑Month Price Target Cut to $4.93, Implies 442% Upside - TradingView
Humacyte (HUMA) Q1 2026 Earnings Transcript - The Globe and Mail
Humacyte Releases Q1 2026 Financial Results - AlphaStreet
Humacyte Q1 2026 Earnings Call Transcript - MarketBeat
BTIG cuts Humacyte stock price target on revenue miss, slower ramp - Investing.com
BTIG cuts Humacyte stock price target on revenue miss, slower ramp By Investing.com - Investing.com South Africa
Humacyte Q1 Earnings Call Highlights - MarketBeat
HUMA: Symvess sales surged, restructuring cut costs, and key clinical milestones are on track for 2026 - TradingView
Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript - Yahoo Finance
Earnings call transcript: Humacyte Q1 2026 EPS beats forecast, revenue misses - Investing.com
HUMA: Symvess sales surged year-over-year, with restructuring and global expansion positioning for growth - TradingView
Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
HUMA: Symvess sales grew, net loss widened, and restructuring cut costs as global expansion advanced - TradingView
Bioengineered blood vessel firm wins Saudi deal and Pentagon backing - Stock Titan
Humacyte Inc (HUMA) Q1 2026 Earnings Call Highlights: Sales Surge and Strategic Expansions Amid ... By GuruFocus - Investing.com Canada
Humacyte Q1 2026 earnings preview - MSN
Humacyte appoints Todd Rasmussen as chief surgical officer By Investing.com - Investing.com South Africa
Humacyte appoints Dr. Todd E. Rasmussen as chief surgical officer - marketscreener.com
Humacyte appoints Todd Rasmussen as chief surgical officer - Investing.com
Humacyte Appoints Todd E. Rasmussen, M.D., as Chief Surgical Officer to Advance Clinical Adoption of Symvess - Quiver Quantitative
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer - The Manila Times
2.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):